دورية أكاديمية
LPS low -Macrophages Alleviate the Outcome of Graft- Versus -Host Disease Without Aggravating Lymphoma Growth in Mice.
| العنوان: | LPS low -Macrophages Alleviate the Outcome of Graft- Versus -Host Disease Without Aggravating Lymphoma Growth in Mice. |
|---|---|
| المؤلفون: | Jeljeli M; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France.; Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, Service d'immunologie biologique, Paris, France., Chêne C; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France., Chouzenoux S; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France., Thomas M; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France., Segain B; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France., Doridot L; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France., Nicco C; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France., Batteux F; Département 3I «Infection, Immunité et Inflammation», Institut Cochin, INSERM U1016, Université de Paris, Paris, France.; Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, Service d'immunologie biologique, Paris, France. |
| المصدر: | Frontiers in immunology [Front Immunol] 2021 Aug 03; Vol. 12, pp. 670776. Date of Electronic Publication: 2021 Aug 03 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation*, Graft vs Host Disease/*immunology , Lymphoma/*immunology , Macrophages/*immunology , T-Lymphocytes/*immunology, Animals ; Carcinogenesis ; Cell Proliferation ; Cells, Cultured ; Cellular Reprogramming ; Female ; Immune Tolerance ; Interleukin-10/metabolism ; Lipopolysaccharides/metabolism ; Macrophages/transplantation ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Transplantation, Homologous |
| مستخلص: | Despite significant therapeutic advances, graft- versus -host disease (GvHD) remains the main life-threatening complication following allogeneic hematopoietic stem cell transplantation. The pathogenesis of GvHD is dominated by a dysregulated allogeneic immune response that drives fibrosis and autoimmunity in chronic forms. A multitude of cell therapy approaches, including infusion of myeloid cells, has been proposed to prevent GvHD through tolerance induction but yielded variable results. Myeloid cells like macrophages can be reprogrammed to develop adaptive-like features following antigenic challenge to reinforce or inhibit a subsequent immune response; a phenomenon termed 'trained immunity'. Here we report that, whereas LPS low -trained macrophages elicit a suppressor effect on allogeneic T cell proliferation and function in vitro in an IL-10-dependent manner, Bacille Calmette et Guérin (BCG)-trained macrophages exert an opposite effect. In a murine model of sclerodermatous chronic GvHD, LPS low -trained macrophages attenuate clinical signs of GvHD with significant effects on T cell phenotype and function, autoantibodies production, and tissue fibrosis. Furthermore, infusion of LPS low -macrophages significantly improves survival in mice with acute GvHD. Importantly, we also provide evidence that LPS low -macrophages do not accelerate A20-lymphoma tumor growth, which is significantly reduced upon transfer of BCG-macrophages. Collectively, these data indicate that macrophages can be trained to significantly inhibit in vitro and in vivo allo-reactive T cell proliferation without exhibiting pro-tumoral effect, thereby opening the way to promising clinical applications. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Jeljeli, Chêne, Chouzenoux, Thomas, Segain, Doridot, Nicco and Batteux.) |
| References: | Br J Haematol. 2016 Apr;173(2):190-205. (PMID: 27019012) Clin Exp Immunol. 2006 Jul;145(1):36-43. (PMID: 16792671) J Invest Dermatol. 2009 Apr;129(4):879-90. (PMID: 19005490) Immunity. 2014 Jul 17;41(1):49-61. (PMID: 25035953) J Transl Med. 2016 Nov 22;14(1):323. (PMID: 27876058) Blood. 2011 Mar 24;117(12):3268-76. (PMID: 21245483) Science. 2016 Apr 22;352(6284):aaf1098. (PMID: 27102489) Front Immunol. 2019 May 21;10:1109. (PMID: 31178861) J Clin Invest. 2017 Jun 30;127(7):2452-2463. (PMID: 28665299) PLoS Pathog. 2011 Jul;7(7):e1002098. (PMID: 21814510) Immunol Allergy Clin North Am. 2010 Feb;30(1):75-101. (PMID: 20113888) J Immunol. 2002 Mar 15;168(6):3088-98. (PMID: 11884483) Ther Adv Hematol. 2013 Dec;4(6):366-78. (PMID: 24319572) Bone Marrow Transplant. 2017 Jan;52(1):88-94. (PMID: 27376453) J Immunol. 2006 Jun 15;176(12):7394-401. (PMID: 16751384) J Immunol. 2005 Mar 1;174(5):3051-8. (PMID: 15728519) Blood. 2010 Dec 16;116(25):5738-47. (PMID: 20807889) Blood. 2003 Mar 1;101(5):1677-82. (PMID: 12406880) J Immunol. 1979 Feb;122(2):549-54. (PMID: 310843) Nat Rev Immunol. 2013 Dec;13(12):862-74. (PMID: 24232462) Cell Host Microbe. 2012 Aug 16;12(2):223-32. (PMID: 22901542) Immunity. 2005 Oct;23(4):445-58. (PMID: 16226509) Int J Biomed Sci. 2005 Jun;1(1):46-52. (PMID: 23674953) Nature. 2014 Oct 23;514(7523):450-4. (PMID: 25274301) J Clin Oncol. 2011 Jun 1;29(16):2230-9. (PMID: 21464398) Biol Blood Marrow Transplant. 2015 Mar;21(3):569-74. (PMID: 25528387) Front Immunol. 2018 Dec 21;9:3041. (PMID: 30619371) Blood. 2012 Nov 15;120(20):4246-55. (PMID: 23012327) J Immunol. 2008 May 1;180(9):5771-7. (PMID: 18424693) J Immunol Res. 2016;2016:4048235. (PMID: 27833923) Front Immunol. 2016 Aug 10;7:304. (PMID: 27559335) Curr Opin Hematol. 2006 Nov;13(6):426-35. (PMID: 17053454) Genes Immun. 2009 Dec;10(8):687-701. (PMID: 19571824) Hepatol Res. 2003 May;26(1):1-9. (PMID: 12787797) Front Pharmacol. 2012 Feb 24;3:23. (PMID: 22375119) J Immunol. 1999 Nov 15;163(10):5693-9. (PMID: 10553100) Blood. 1998 Dec 1;92(11):4212-9. (PMID: 9834226) Int J Clin Exp Pathol. 2014 Sep 15;7(10):6626-34. (PMID: 25400741) Semin Immunol. 2016 Aug;28(4):343-50. (PMID: 26979658) Mol Immunol. 2010 Jun;47(10):1882-9. (PMID: 20417561) Leukemia. 2020 Mar;34(3):895-908. (PMID: 31719679) J Immunol. 1998 Nov 1;161(9):4688-94. (PMID: 9794398) J Innate Immun. 2014;6(2):152-8. (PMID: 24192057) Int J Hematol. 2011 May;93(5):571-577. (PMID: 21384095) J Immunol. 2012 May 15;188(10):5142-9. (PMID: 22491256) J Immunol. 1999 Apr 1;162(7):4037-44. (PMID: 10201926) Br J Haematol. 2006 Jun;133(5):538-49. (PMID: 16681643) Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33. (PMID: 22766220) Exp Cell Res. 2011 Mar 10;317(5):620-31. (PMID: 21376175) J Immunol Methods. 2011 Oct 28;373(1-2):161-6. (PMID: 21889511) J Immunol. 1997 Jun 15;158(12):5791-6. (PMID: 9190930) Front Immunol. 2016 Nov 29;7:539. (PMID: 27965667) Mol Cells. 2015 Oct;38(10):886-94. (PMID: 26429502) Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. (PMID: 27713092) Trends Cancer. 2020 Jul;6(7):580-592. (PMID: 32610068) Biomedicines. 2017 Jul 01;5(3):. (PMID: 28671556) Br J Haematol. 1994 Jun;87(2):415-8. (PMID: 7947291) Annu Rev Immunol. 2018 Apr 26;36:411-433. (PMID: 29677473) J Cell Biochem. 2019 Mar;120(3):2756-2765. (PMID: 30270458) J Immunol. 2007 Jun 1;178(11):6840-8. (PMID: 17513732) Blood. 2001 Sep 1;98(5):1607-13. (PMID: 11520814) Nat Rev Immunol. 2020 Jun;20(6):375-388. (PMID: 32132681) Cell Rep. 2020 Nov 3;33(5):108325. (PMID: 33147452) Cell. 2018 Jan 11;172(1-2):176-190.e19. (PMID: 29328912) Nat Commun. 2019 Dec 11;10(1):5670. (PMID: 31827093) J Immunol. 2016 Mar 1;196(5):2167-80. (PMID: 26810222) J Exp Med. 2011 May 9;208(5):1069-82. (PMID: 21536742) Trends Immunol. 2009 Oct;30(10):475-87. (PMID: 19781994) Blood. 2017 Jan 5;129(1):13-21. (PMID: 27821504) Sci Rep. 2019 Feb 11;9(1):1759. (PMID: 30741975) J Clin Invest. 1999 Jul;104(1):49-57. (PMID: 10393698) J Immunol. 2008 Dec 1;181(11):7581-92. (PMID: 19017947) Trials Vaccinol. 2014;3:1-5. (PMID: 24611083) J Invest Dermatol. 2012 Dec;132(12):2752-61. (PMID: 22810302) Blood. 2015 Jan 22;125(4):606-15. (PMID: 25398933) Microbiol Spectr. 2016 Aug;4(4):. (PMID: 27726767) J Immunol. 1988 Jan 15;140(2):531-6. (PMID: 3257243) Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S56-61. (PMID: 22226114) J Leukoc Biol. 2017 Jan;101(1):107-119. (PMID: 27780875) Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42. (PMID: 22988082) Sci Rep. 2016 Aug 05;6:30802. (PMID: 27492684) Immunol Res. 1996;15(1):50-73. (PMID: 8739565) Front Immunol. 2019 Feb 22;10:163. (PMID: 30853956) Front Immunol. 2018 Jun 22;9:1461. (PMID: 29988391) Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S46-52. (PMID: 22226112) J Immunol. 2001 Nov 15;167(10):5741-8. (PMID: 11698447) Blood. 2018 Mar 29;131(13):1399-1405. (PMID: 29437591) Ann Surg. 1974 Oct;180(4):635-43. (PMID: 4412271) Blood. 2004 Sep 1;104(5):1565-73. (PMID: 15150080) Eur J Clin Invest. 2013 Aug;43(8):881-4. (PMID: 23869409) Immunology. 2011 Apr;132(4):567-77. (PMID: 21255011) Front Immunol. 2017 Mar 20;8:79. (PMID: 28373870) Nat Rev Immunol. 2012 May 11;12(6):443-58. (PMID: 22576252) Front Immunol. 2019 Jun 04;10:1267. (PMID: 31214200) Cell Stem Cell. 2014 Nov 6;15(5):605-18. (PMID: 25312494) Nat Med. 2012 Jul 06;18(7):1028-40. (PMID: 22772564) Nat Rev Urol. 2018 Oct;15(10):615-625. (PMID: 29991725) Dis Model Mech. 2011 May;4(3):318-33. (PMID: 21558065) |
| فهرسة مساهمة: | Keywords: alloimmunity; anti-tumoral action; graft-versus-host disease; inflammation; macrophages; trained immunity |
| المشرفين على المادة: | 0 (Lipopolysaccharides) 130068-27-8 (Interleukin-10) |
| تواريخ الأحداث: | Date Created: 20210820 Date Completed: 20211101 Latest Revision: 20211101 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8369416 |
| DOI: | 10.3389/fimmu.2021.670776 |
| PMID: | 34413847 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2021.670776 |